AB&B BIO-TECH-B(02627)'s subsidiary WiseCornxin is the only vaccine selected for the preliminary review list of national medical insurance innovative drugs.

AB&B BIO-TECH-B (02627) announced that according to the announcement released by the National Medical Security Administration on August 12, 2025, this year's national commercial health insurance innovative drug catalog includes the only vaccine product - quadrivalent influenza virus subunit vaccine. The Group's product, named Huierkangxin quadrivalent influenza virus subunit vaccine, obtained a New Drug Application (NDA) approval from the China National Medical Products Administration in May 2023, and can be used for individuals aged three and above (with a specification of 15g/0.5ml in terms of virus strain hemagglutinin concentration). It is the first and only quadrivalent influenza virus subunit vaccine approved in China as of July 21, 2025, aiming to provide broad protection against two types of influenza A viruses (H1N1 and H3N2 subtypes) and two types of influenza B viruses (Yamagata and Victoria lineages). This product has undergone significant upgrades from traditional virus split vaccines, with advantages such as comprehensive protection, high purity of component antigens, and low risk of adverse reactions.